Sesh Products US Inc., an Austin, Texas-based oral nicotine company, has announced that the U.S. Food and Drug Administration has determined its bundled Premarket Tobacco Product Application covering 64 stock-keeping units meets filing requirements and is now eligible to enter the substantive scientific review phase, the final stage before a marketing order decision is issued. The application covers the company’s Sesh+ line of nicotine pouches across multiple flavour variants, nicotine strengths, and packaging configurations targeting adult consumers aged 21 and over.
What the filing determination actually means for Sesh and where it sits in the PMTA process
The FDA’s filing determination is frequently misread as an endorsement of the underlying science, but it is not. It signals only that the Center for Tobacco Products has concluded the submission is sufficiently complete to proceed. The agency has explicitly stated that a filing decision does not reflect any evaluation of the adequacy of the data and carries no presumption of approval. What it does do is formally move Sesh into a much more demanding phase, where reviewers assess whether permitting the product’s marketing is appropriate for the protection of public health under Section 910 of the Federal Food, Drug, and Cosmetic Act. That statutory standard requires weighing benefits to current adult nicotine users against population-level risks, including youth uptake.
The distinction matters commercially as well as regulatorily. Products that clear filing review remain in a legal grey zone: they can continue to be marketed under enforcement discretion, but they are not authorised. A marketing order, if granted, would represent genuine FDA approval and would substantially reduce the regulatory risk that hangs over every brand operating without one. For an independent company in Sesh’s position, the difference between those two states is significant.
How Sesh’s regulatory position compares with authorised and pending pouch applications
As of early 2026, only 26 nicotine pouch products hold FDA marketing authorisation in the United States. Philip Morris International’s ZYN line of 20 variants received its marketing granted order in January 2025 after a review process that stretched across nearly five years from submission. Six on! PLUS pouches from Helix Innovations, an Altria subsidiary, received authorisation in December 2025 under an expedited FDA pilot program designed to streamline reviews for a subset of high-profile applicants that included Philip Morris International, Reynolds American, and Turning Point Brands. Sesh was not included in that pilot cohort.
That distinction matters because the pilot program compressed ZYN’s successor application and on! PLUS reviews to roughly three months, whereas Sesh’s original bundled PMTA covering 72 SKUs was accepted for review in October 2023 and spent more than two years in prefiling assessment before the current 64-SKU version cleared the filing threshold. Industry observers tracking the category note that smaller independent brands face structural disadvantages in FDA’s queue, partly because the agency’s real-time communication resources and expedited pathways have been directed toward manufacturers with the largest market footprints and deepest scientific dossiers.
Why an independent pouch maker reaching substantive review is a harder achievement than it appears
The PMTA process is resource-intensive in ways that disproportionately challenge companies outside the major tobacco conglomerates. Applicants must demonstrate, across multiple scientific disciplines, that their product’s marketing is appropriate for the public health when considered from the perspective of the entire population, not just existing adult users. That requires toxicology data, abuse liability assessments, perception and use studies, pharmacokinetics data, and marketing analysis covering youth exposure and appeal. ZYN’s successful application, which the FDA reviewed over five years, ran to hundreds of thousands of pages.
Sesh has positioned itself as an exception among independent pouch brands, having submitted early and maintained continuous regulatory engagement. The company has raised more than US$40 million in venture funding, which has supported both its national convenience retail distribution network and, according to the company’s public statements, sustained scientific and regulatory investment. The founding team’s connection to Swedish Match’s Sesh+ formulation heritage, via inventor Thomas Ericsson’s involvement, may also have shaped the scientific architecture of the application. Whether that foundation is sufficient for the FDA’s full substantive review remains to be seen.
What substantive review will examine and where the evidentiary risks are concentrated
FDA’s substantive scientific review will interrogate several layers of evidence that filing review does not touch. Reviewers in the Center for Tobacco Products will assess the product’s harmful and potentially harmful constituent profile, comparing levels against both combustible cigarettes and authorised smokeless alternatives. The on! PLUS authorisation offers a useful reference point: the FDA found that those products contained lower levels of most carcinogenic HPHCs compared with other oral and smokeless tobacco products, with several below measurable limits. Whether Sesh’s formulation achieves comparable constituent levels is a central question that the substantive review will address.
Beyond chemistry, the review will scrutinise behavioural science data. The FDA’s ZYN authorisation highlighted the importance of prospective cohort data showing switching from combustible cigarettes, and the on! PLUS review suggested the agency is cautiously moving toward accepting dual-use reduction as a transitional benefit, provided cigarette consumption declines by more than half. Sesh will need credible data on actual use patterns among its consumer base, including evidence that its marketing channels, which include major convenience retail chains with broad consumer exposure, do not generate disproportionate youth initiation. That last point is the most politically sensitive dimension of any nicotine pouch review in the current regulatory climate.
How the FDA’s nicotine pouch pilot program reshaped the competitive landscape for independents
The FDA launched its nicotine pouch PMTA pilot in September 2025 with stated goals of increasing review efficiency and focussing assessments on the most critical evidentiary elements for the product category. The practical consequence, which industry observers flagged at the time, was that large-manufacturer applications moved ahead of independent submissions that had been in the queue for longer. Sesh’s application had been under review since late 2023, yet it did not feature in the pilot cohort. The pilot’s success in delivering the on! PLUS authorisation within three months has now raised the question of whether any form of expedited pathway will be extended to smaller applicants.
Regulatory watchers suggest the FDA’s pilot architecture was designed primarily to demonstrate that the agency could process high-volume, well-resourced applications efficiently, not necessarily to create a replicable model for all pending pouch PMTAs. The agency has stated it intends to evaluate the pilot’s effectiveness before potentially incorporating process improvements into the broader PMTA program. That evaluation timeline is undefined, which leaves independent brands with applications in substantive review operating under the same uncertain waiting conditions that characterised the pre-pilot era.
What a marketing order would mean commercially and what risks remain between now and a decision
A successful marketing order would transform Sesh’s legal and commercial standing in ways that go beyond regulatory compliance. It would allow the company to make explicit public health comparisons with combustible cigarettes in marketing materials, a communication advantage currently available only to ZYN and on! PLUS among pouch brands. It would also provide a structural competitive moat at a time when the nicotine pouch market, projected by some industry analysts to grow from roughly US$4 billion in 2023 to nearly US$50 billion by 2033 [SINGLE SOURCE – VERIFY], is attracting intense competition from both tobacco conglomerates and new entrants.
The risks between now and a decision are layered. The FDA could issue a deficiency letter requesting additional data, effectively restarting the evidentiary clock on specific questions. It could issue a marketing denial order if it concludes the population health calculus does not favour authorisation. Political and institutional dynamics within the Center for Tobacco Products, which operates under evolving leadership priorities, could also affect timelines. Anti-tobacco advocacy groups have been consistent in urging the FDA to maintain rigorous youth appeal assessments for all oral nicotine products, and those pressures are unlikely to diminish during Sesh’s review.
What clinicians and regulators tracking the category will watch most closely is whether the FDA’s handling of Sesh’s application reflects any broadening of the expedited review framework beyond its initial pilot beneficiaries. An authorisation for an independent brand, navigating the full PMTA process without conglomerate resources, would represent a qualitatively different signal from the market than the ZYN and on! PLUS decisions, and would carry implications for the broader ecosystem of smaller tobacco harm reduction companies awaiting outcomes.
Sesh Products clears PMTA filing threshold as FDA substantive review begins added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →